GenrAb

Dallas, United States

GenrAb uses the power of adaptive human immunity to develop neuroprotective and neurotherapeutic human antibodies.

$5.6M raised

Apr 2025

Seed

Top Investors

Actium Group

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has GenrAb raised?

GenrAb has raised $5.6M in total funding. The most recent round was Seed. The last funding was announced in April 2025.

Who are GenrAb's investors?

GenrAb's investors include Actium Group.

Where is GenrAb headquartered?

GenrAb is headquartered in Dallas, United States.

What does GenrAb do?

GenrAb uses the power of adaptive human immunity to develop neuroprotective and neurotherapeutic human antibodies.

What stage is GenrAb at?

GenrAb is at the Seed stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated April 22, 2025.

MLA

"GenrAb — Funding & Investors." VCBacked, April 22, 2025, https://www.vcbacked.co/company/genrab. Accessed June 11, 2026.

APA

VCBacked. (2025). GenrAb — Funding & Investors. Retrieved June 11, 2026, from https://www.vcbacked.co/company/genrab

Wikipedia (cite web)

{{cite web |title=GenrAb — Funding & Investors |url=https://www.vcbacked.co/company/genrab |website=VCBacked |access-date=June 11, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated April 22, 2025.